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Cardiovascular magnetic resonance (CMR) imaging is a versatile tool that has established
itself as the reference method for functional assessment and tissue characterisation.
CMR helps to diagnose, monitor disease course and sub-phenotype disease states.
Several emerging CMR methods have the potential to offer a personalised medicine
approach to treatment. CMR tissue characterisation is used to assess myocardial
oedema, inflammation or thrombus in various disease conditions. CMR derived scar
maps have the potential to inform ablation therapy—both in atrial and ventricular
arrhythmias. Quantitative CMR is pushing boundaries with motion corrections in
tissue characterisation and first-pass perfusion. Advanced tissue characterisation by
imaging the myocardial fibre orientation using diffusion tensor imaging (DTI), has
also demonstrated novel insights in patients with cardiomyopathies. Enhanced flow
assessment using four-dimensional flow (4D flow) CMR, where time is the fourth
dimension, allows quantification of transvalvular flow to a high degree of accuracy for
all four-valves within the same cardiac cycle. This review discusses these emerging
methods and others in detail and gives the reader a foresight of how CMR will evolve into
a powerful clinical tool in offering a precision medicine approach to treatment, diagnosis,
and detection of disease.
Keywords: cardiovascular magnetic resonance, diffusion tensor imaging, tissue characterisation, myocardial
fibrosis, four-dimensional flow imaging
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INTRODUCTION
Non-invasive imaging plays a fundamental role in the assessment
of cardiovascular disease. Cardiovascular magnetic resonance
(CMR) is now considered the gold standard imaging technique
for the assessment of myocardial anatomy, regional and global
function, and viability. More recently, novel methods of
CMR are pushing the boundaries of diagnosis and allowing
CMR to guide treatment whilst also further sub-phenotyping
cardiovascular diseases.
Myocardial tissue characterisation has undoubtedly been
proven to be an invaluable tool for clinicians as it often
provides the diagnosis, therefore enabling the most appropriate
treatment option. Established techniques, including native T1-
mapping, extracellular volume (ECV) quantification, and T2-
mapping, are used in clinical practise routinely not only to
differentiate cardiomyopathies but also to provide information
on the extent of myocardial disease as evidenced by oedema
and/or fibrosis encountered in several disease processes that
affect the myocardium. CMR also allows individualised planning
of invasive management strategies against arrhythmias. More
specifically, localisation of the scar tissue can provide invaluable
information for targeted ablation treatment strategies.
More advanced techniques, such as quantitative perfusion
CMR and diffusion tensor imaging (DTI), have shown promising
advancements that further support the transition of their use
from research to the clinical practise. Moreover, novel methods
such as the four-dimensional (4D) flow CMR have revolutionised
the field as it allows direct evaluation of the flow in all
three directions. The information provided by 4D flow can be
vital in the assessment of conditions such as complex valvular
lesions or congenital heart diseases, in which the haemodynamic
patterns and effects have been difficult to visualise with other
imaging modalities.
CMR therefore plays an important role in several aspects
of clinical practise having significant impact on the diagnostic,
prognostic and treatment pathways in patient care. In this
comprehensive review, we first discuss established methods of
CMR and then describe important emergingmethods which have
the potential for clinical impact and are likely to influence the
future role of CMR.
TISSUE CHARACTERISATION
CMR is now established for myocardial tissue characterisation
and allows the assessment of myocardial oedema, microvascular
obstruction, thrombus, and scar (1). Clinical use includes—
T2-weighted STIR (short tau inversion recovery) imaging for
myocardial oedema and intra-myocardial haemorrhage post-
acute myocardial infarction (MI), early gadolinium enhancement
(EGE) for thrombus and microvascular obstruction and late
gadolinium enhancement (LGE) for the myocardial scar. The
pattern of the myocardial scar on LGE can sub-phenotype
the disease process (2). In addition, a combination of the
aforementioned methods can further differentiate acute from
chronic MI (3), cause of heart failure (HF) or cardiomyopathy (4,
5). Importantly, visual identification of LGE has been associated
with worse prognosis across a wide series of pathologies,
including aortic stenosis, cardiomyopathies, and congenital
heart disease (6–8). Furthermore, myocardial and liver iron
content quantification by T2∗ magnetic resonance has been
well-established in the management of conditions with iron-
overload and particularly in the serial follow-up of patients
with thalassaemia (9). These standard methods have some
limitations—they are predominantly non-quantitative methods,
which might limit their standardisation and utilisation as
endpoints in clinical trials. Whilst quantification of LGE is
being investigated in the research arena, and higher LGE mass
has been associated with worse prognosis, this is not being
routinely utilised (10, 11). Also, these are two-dimensional
acquisitions which limit full left ventricular (LV) coverage
for either diagnosis or therapeutic reasons, for example, in
ventricular tachycardia (VT) ablation (12). Here we describe
emerging CMR tissue characterisation methods that have
the potential for improving diagnosis, informing treatment,
and outcomes.
SCAR MAPPING BY LGE IMAGING FOR
ARRHYTHMIC ABLATION THERAPY
The presence of myocardial scar and its characteristics define
the arrhythmogenic substrate (13, 14). In particular, the partially
infarcted myocardial tissue, named the grey zone, has been
shown to be an important predictor of adverse cardiac events,
outperforming traditional functional parameters such as left
ventricular ejection fraction (15, 16). More recently, the deep
channels, islets of alive myocytes sandwiched between two
discrete infarcted regions have been identified as areas of
late potential, which can be targeted for ablation (Figure 1)
(17). Translational studies have already demonstrated that the
arrhythmogenic deep channel ablation, identified by using LGE
imaging, can reduce arrhythmic burden and recurrence over
electrical mapping techniques. In addition, scar localisation
(epicardial vs. subendocardial) allows planning for either an
endocardial or epicardial approach for ablation. For example,
for ablation of interventricular septum ventricular tachycardia,
epicardial access is typically not required. This has the huge
potential to save time in the catheter laboratories, reduce
patient risk and discomfort and overall demonstrate promising
outcome results. To map the core scar, grey zone, and the
deep channels, a three-dimensional (3D) coverage of the left
ventricle or the atrium is necessary. A proposed solution
is to acquire short-axis and long-axis stacks of the region
of interest and generate a high-resolution 3D stack using
this (18). With the emergence of novel acceleration methods,
including compressed sensing, it is now possible to do 3D
LGE imaging with full coverage of the LV or left atrium
(LA) for informing ablation therapy. CMR-aided scar de-
channelling results in a lower need for radio-frequency delivery,
higher rates of non-inducibility after substrate ablation, and
VT-recurrence-free survival (17). However, integrated software
solutions are needed to push this emerging method into routine
clinical practice.
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FIGURE 1 | Scar mapping. (A) Short-axis, two-dimensional segmentation of scar and border zone. (B) These are high-resolution signal intensity maps generated
using two 2D LGE acquisitions. Full-width half max threshold of 60% has been applied to identify the infarct core—the red areas. The orange arrow demonstrates the
presence of deep channel with late action potential which was ablated for this patient.
QUANTITATIVE TISSUE
CHARACTERISATION
In the last 5-years, several CMR relaxometry-based quantitative
techniques have translated into routine clinical practice to
inform diagnosis and guide treatment (19, 20). The most
common ones are native T1-mapping, extracellular volume
(ECV) quantification using native/post-contrast T1-mapping
methods, T2-mapping, and T2∗-mapping. These techniques
are now established to sub-phenotype cardiomyopathies and
differentiate the aetiology of myocardial infarction with non-
obstructive coronary arteries (MINOCA) in an acute setting
(Figure 2) (21). A case example of Takotsubo cardiomyopathy
diagnosed acutely on multi-parametric CMR is demonstrated
in Figure 3. In addition, native-T1 and ECV mapping allow
quantifying infarct size, area at risk, and myocardial salvageable
index (MSI) in an acute infarct setting (22, 23). In patients who
have contraindications for gadolinium-based contrast agents,
native-T1 allows making some degree of infarct assessment;
however, as it is less specific, it is not always possible to infer
infarct using this method alone. Diagnostic strengths of native
T1 vs. ECV are shown in Figure 4.
In recent years, the focus of the assessment and risk
stratification of patients with valvular lesions has shifted towards
the myocardium. For example, in the case of aortic stenosis, there
remains a major uncertainty regarding the timing of intervention
in asymptomatic patients. Myocardial fibrosis in aortic stenosis
is mainly a result of chronically elevated left ventricular afterload,
which is associated with several pathological changes, including
cellular hypertrophy, expansion of the extracellular matrix (or
volume), and ischaemia due to demand-supply mismatch (24).
Several studies have shown that once replacement fibrosis ensues,
it progresses rapidly and is unlikely to improve following aortic
valve replacement (25, 26), diffuse fibrosis indexed for the left
ventricular volumemeasured by the indexed ECV (iECV) regress
after aortic valve intervention (25, 26). Following correction of
the afterload issue by valve intervention, the left ventricular
mass decreases with regression of both cellular and extracellular
mass, but cellular mass regresses more, hence resulting in relative
increase in ECV% as the ratio of matrix to total mass is
increased. However, the iECV decreases as it represents the
extracellular matrix as a total volume, rather than a percentage
which is therefore in keeping with the potential for reversal of
diffuse fibrosis. Clinical trials, including the EVOLVED trial,
are investigating the role of myocardial fibrosis assessment as a
trigger for intervention (27). Quantitative tools (T1-mapping and
ECV) for mapping diffuse fibrosis are of particular interest in
aortic stenosis. There is some evidence that myocardial fibrosis
mapped using these tools is associated with histology in aortic
stenosis (28, 29); they can detect ventricular decompensation
(24), further risk stratification, and predict adverse outcomes
offering incremental value to LGE (30, 31).
In the case of the mitral valve, the role of diffuse myocardial
fibrosis assessment by mapping techniques is less established.
A study by Edward et al. (32) demonstrated the ECV in
patients with asymptomatic primary mitral regurgitation to be
raised. In addition, ECV was associated with two previously
defined important prognosis markers—end-systolic volume and
left atrial volume, and with peak VO2 max (r-0.51, P < 0.05).
Furthermore, the impact of diffuse fibrosis on patients symptoms
and ventricular response following surgery is being addressed by
the FINDER study (33).
QUANTITATIVE MYOCARDIAL PERFUSION
Vasodilator stress perfusion CMR imaging has evolved into
a recognised form of assessment for patients with known or
suspected cardiac chest pain for the identification of myocardial
ischaemia. Visual assessment involves identification of delayed
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FIGURE 2 | Tissue characterisation using native T1 and ECV. Absolute values for native T1 depend greatly on field strength (1.5 or 3 T), pulse sequence (MOLLI or
ShMOLLI), scanner manufacturer and rules of measurements. For the purpose of comparability, only studies using MOLLI sequences were considered in this figure.
AL, amyloid light chain; ATTR, amyloid transthyretin; DCM, dilated cardiomyopathy; ECV, extracellular volume; HCM, hypertrophic cardiomyopathy; MI, myocardial
infarction; RA, rheumatoid arthritis; TC, takotsubo cardiomyopathy.
first-pass wash-in of gadolinium-based contrast agent, from
epicardial to endocardial layers in one or more myocardial
segments. By comparison with single photon emission computed
tomography (SPECT), perfusion CMR allows better assessment
of transmural perfusion due to its high spatial resolution and has
been shown to be superior in the evaluation of left main stenosis
(34) and in assessment of women with suspected ischaemia (35).
First-pass perfusion images are usually acquired by a dynamic
T1-weighted sequence; this is meant to generate a contrast
between zones of stress-induced hyperaemic myocardium and
zones of relatively reduced perfusion, based on the distinct
speed of inflow of blood and gadolinium over time. Typically
stress images are performed under vasodilator (adenosine,
dipyridamole, or regadenoson) stress followed by rest images,
which comprise the same sequence without the vasodilator
effect, usually as three short axis (basal, mid, and apex) slices.
Automated inline quantification enables the user to obtain
myocardial blood flow (MBF) at stress and rest. Using the values
of stress and rest MBF, a ratio known as the myocardial perfusion
can be obtained.
Despite the more widespread availability of CMR in recent
years, quantitative perfusion CMR has remained largely a
research tool, and perfusion CMR is assessed visually in the
clinical setting. Clinical perfusion CMR compares well to invasive
angiography (36, 37), fractional flow reserve (FFR) (38–42), and
single positron emission computed tomography (SPECT) (43–
45), and has demonstrated good prognostic value (46–48).
Over the past three decades, quantitative perfusion CMR
has been described (47, 48), refined, and subsequently validated
against FFR (40, 49), microspheres (50), and more recently
against PET (51, 52). Though PET remains the non-invasive
reference method for perfusion quantification, it involves the use
of ionising radiation and requires an on-site cyclotron.
The aim of a quantitative approach is to enable user-
independent and reproducible measurements of myocardial
perfusion. This is especially pertinent in cases where perfusion
abnormalities are diffuse as visual assessment can be challenging.
In the case of multi-vessel disease, a quantitative approach has
been shown to be superior to visual assessment (53). Similarly,
in an observational registry, the use of a quantitative approach
proved it could provide incremental prognostic benefit over a
visual approach (54).
Lack of standardisation appears to be the limiting factor
to more widespread implementation of quantitative perfusion
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FIGURE 3 | Multi-parametric tissue characterisation of the myocardium to aid diagnosis. This is a case of a 57 year old lady who presents with acute chest pain, ST
elevation, and raised troponin biomarkers. Her coronary angiogram was normal. An acute CMR revealed apical ballooning demonstrated in the 4CH view by orange
arrows, rise in myocardial oedema on T2-weigthed imaging and confirmed on quantitative native T1-maps (white arrows). There was no evidence of scar on late
gadolinium enhancement imaging and overall the extracellular volume was relatively not high as T1-values. This is suggestive of more intra-cellular swelling than
extracellular expansion in an acute setting.
FIGURE 4 | Diagnostic complementary utility of native T1-mapping vs. ECV.
The main advantage of ECV is that it takes gadolinium flow kinetics into
consideration to improve the precision of diagnosis.
CMR particularly in regards to acquisition and dosing protocols,
analysis methods, and the availability of software for post-
processing across centres. The last few years, however, have
seen significant steps towards more user-friendly quantitative
approaches to drive towards clinical translation. Using a
dual-sequence approach, Kellman et al. have achieved inline
myocardial perfusion quantification allowing fast results with
minimal user interaction (Figure 5). This approach has been
validated in healthy volunteers (55, 56), in patients with known
or suspected coronary artery disease (CAD) against angiography
(56) and in patients against PET (57). Other recent studies
have explored the use of perfusion mapping against angiography
(58), deep learning-based processing of perfusion data (59), and
most recently, artificial intelligence quantification of perfusion
mapping was shown to be a strong, independent predictor of
adverse cardiovascular outcome (60).
Perfusion quantification is based on the indicator-dilution
principle (61). A recognised amount of an indicator is injected
into a fluid flowing at an unknown rate. This is through
a system of unknown volume. The fluid is monitored at
different points downstream from the plane of introduction
and the concentration of indicator, diluted by the parent fluid,
is measured as a function of time. In first-pass perfusion,
the “indicator” is usually a gadolinium-based contrast agent
introduced via a peripheral vein. Because the concentration of
contrast at the ostium of the coronary arteries is not known, the
quantity is estimated by measuring the arterial first-pass time-
intensity curve (arterial input function, AIF) of the left ventricle.
Finally, myocardial blood flow is observed as a function of the
quantified myocardial time-intensity curve (62).
Here lies one of the main hurdles in quantification of
perfusion CMR—at lower doses, the dose-signal relationship
is linear. However, at higher doses, there is saturation of
the gadolinium signal curves, which, if uncorrected, can lead
to elevated and non-physiological perfusion estimates. As a
result, the bulk of the study on quantitative perfusion research
has focused on optimisation of approaches to overcome this
challenge by addressing various dosing regimes, acquisition
protocols, manipulation of magnetic signal, and complex
mathematical processing.
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FIGURE 5 | Stress perfusion CMR images obtained by automated in line quantification as well as the basal, mid, and apical slices that were obtained in a healthy
volunteer showing no inducible ischaemia, in a patient with a myocardial infarction showing inducible ischaemia in the basal to apical septal and inferior segments and
in a patient with hypertrophic cardiomyopathy demonstrating globally reduced myocardial blood flow secondary to severe microvascular disease.
Early studies simply used lower doses of gadolinium to
avoid saturation effects in combination with strongly T1
weighted sequences—this overcame saturation at higher doses,
but however resulted in low myocardial contrast-to-noise ratio,
and poor visualisation of perfusion abnormalities (63–65).
There are currently two main approaches to obtaining
perfusion-imaging data that can be both visually assessed and
quantified; the dual bolus and dual sequence approaches. The
dual-bolus method is a combination of a low-high dosage
approach, using two consecutive injections of gadolinium
contrast (66–69). In short, this is attained by using a combination
of a body weight-adjusted and high-dose main bolus of contrast
agent preceded by the injection of a low dose pre-bolus having
the same volume of the bolus but only 10% of the concentration
of gadolinium. The pre-bolus low dosage injection allows the
acquisition of a non-saturated AIF. The main bolus injection
produces a desired myocardial signal response for both visual
and quantitative assessment. The dual-sequence method is a
more recently described alternative to the dual-bolus approach,
which has gained momentum in recent years (70–72). In this
approach, for each cardiac cycle a low-resolution image, with a
short saturation- recovery time after the R-wave is acquired to
measure the AIF. This avoids any AIF saturation. Low-resolution
acquisition is followed by high-resolution acquisition with longer
saturation-recovery time to measure the myocardial signal with
higher contrast. There are pros and cons associated with both
methods; the dual-bolus protocols are feasible in the majority
of centres and do not require new software or hardware, but
Frontiers in Cardiovascular Medicine | www.frontiersin.org 6 July 2021 | Volume 8 | Article 682027
Paddock et al. Cardiac MRI: A Comprehensive Review
the preparation of the scan is more complex. Conversely, the
dual-sequence protocols are more straightforward to implement
but widespread use is limited by availability across different
scanner vendors.
Following the acquisition of suitable data by either dual
bolus or dual-sequence methods, the data must then be
analysed to provide stress and rest perfusion estimates and
then in turn myocardial perfusion reserve. Myocardial perfusion
reserve is arguably more robust as inherent errors within the
mathematical modelling are cancelled out by using a ratio
between stress and rest. The mathematical approaches proposed
are beyond the scope of this review but all rely upon model-
dependent or independent deconvolution processing of the
AIF and myocardial signals to determine myocardial perfusion
(63, 73–84).
Data can be analysed on both a segmental or voxel-wise basis.
When segmental quantitative analysis is performed from high-
resolution images, the spatial resolution of the images is only
partially used, as the signal intensity is sampled transmurally.
Hence, time-intensity curves from subendocardial ischaemic
areas are averaged. This results in partial-volume effects
and possibly reduced sensitivity. High-resolution, voxel-wise
myocardial perfusion assessment offers additional information
on the heterogeneity of myocardial perfusion (50, 80). This
combination of absolute quantification and voxel-level resolution
has the potential for calculation of the true ischaemic burden.
Hence voxel perfusion maps limit partial volume effects and
the influence of other factors such as the LV wall thickness, LV
remodeling, and presence of previous infarction.
High-resolution, voxel-wise perfusion is therefore likely to be
the more robust method for assessment of ischaemic burden,
especially when coupled with full LV coverage enabled by newer
3D perfusion sequences. Though not widely employed, some
have demonstrated that 3D quantitative perfusion analysis is
feasible with good diagnostic accuracy for CAD (85–88).
Hautvast et al. (89) proposed an alternative approach to
exploit and quantify high-resolution perfusion CMR data for
the assessment of transmural gradients. This is based on the
quantification of perfusion gradients between endocardial and
epicardial myocardial layers. The transmural perfusion gradient
(TPG) is defined as the percentage of transmural redistribution
of myocardial blood flow between layers. The optimal diagnostic
threshold for TPG is 20%, which identifies the presence of
haemodynamically significant ischaemia in comparison with FFR
(90) with high sensitivity, specificity, and diagnostic accuracy.
There are several advantages to transmural perfusion gradient
analysis compared to other methods of quantitative analysis.
Firstly, administration of a diluted pre-bolus is not required nor is
the acquisition of rest perfusion images. The method is also more
robust to image homogeneity due to variations in the B1 field,
different coil configurations, different schemes of contrast agent
administration, field strength, and the acquisition pulse sequence
(89, 90).
More recently, another approach, the perfusion dyssynchrony
analysis, has been proposed (91). This examines both the spatial
and temporal dispersion of myocardial signals. The concept rests
on the knowledge that in normal myocardium with preserved
vasodilatory reserve, the myocardium is perfused uniformly
across all segments. The presence of one or more coronary
stenoses influences not only the peak but also the time to peak
myocardial signal. Specifically, in cases of multi-vessel CAD, the
temporal dispersion has been shown to increase in relation to
the number of diseased vessels, using FFR as a correlate for
haemodynamic significance.
In summary, robust quantification of perfusion has been a goal
of many investigators for over two decades. Significant advances
in image acquisition, dosing regimens, and analysis methods,
particularly in recent years, along with robust validation against
a number of techniques, have significantly advanced the field
towards clinical translation.
DIFFUSION TENSOR IMAGING
DTI, also known as diffusion tractography, is an advanced
CMR technique which allows the study of 3-dimensional
whole-organ tissue microstructure, it was initially developed
for static organs such as neurological tracts in the brain
(92, 93). In more recent years cardiac DTI has become a
reality (94). The myocardium has a complex microarchitecture.
This consists of a three-dimensional functional syncytium of
branching and inter-connecting myocytes. These myocytes are
embedded in a collagen matrix. Myocytes are grouped in layers
of 5–10, separated by collagen sheetlets which interconnect
with neighbouring layers (95, 96). In the left ventricle, the
overall direction of myocyte aggregates follows a helical
arrangement running in opposite directions at subendocardial
and subepicardial levels; the helix is right-handed (positive
angulation) at the subendocardium and transitions to being left-
handed (negative angulation) at the subepicardum with myofibre
aggregates in the mid LV layer being orientated transversely (97).
The structure and interplay of the myocytes are intrinsically
linked to cardiac contractility and efficiency and therefore the
opportunity to perform cardiac DTI offers the potential for
deeper understanding of cardiac mechanics in health and disease.
The base principle of DTI involves the imaging of the diffusion
of water. In brief, when water is not bound to tissue, it will
diffuse at the same rate in all directions—this can be visualised
as a sphere. Whereas in a tissue, water will diffuse predominantly
in one direction more than in others—this is known as the
phenomenon of anisotropy. This results in a different diffusion
characteristic that can be seen to progress in different directions
and this diffusion property of water can be used to create a map
of diffusion. This can be applied to a region of interest—the
displacement probability of diffusing water molecules within the
myocardium can be measured and the arrangement of the mean
direction of water diffusion can be reconstructed. In cardiac
imaging, DTI is acquired as a series of two-dimensional short
axis ventricular slices which are then reconstructed in 3D form.
The use of diffusion-sensitising sequences allows calculation of a
set of three eigenvectors with water diffusing more readily along
the myofiber, here the average local myocyte orientation within
the voxel is represented by the first, largest eigenvector (E1).
The second largest eigenvector (E2) corresponds to the average
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local sheetlet direction. The mean helix angle is represented by
E1A. E1A is the angle relative to the local wall tangent plane.
E2A represents the mean intra-voxel sheetlet angle. The “third”
eigenvector is the sheet-normal that is perpendicular to the helix
and sheet plane (also described as the transverse angle). Scalar
metrics such as mean diffusivity (MD) and fractional anisotropy
(FA) allow phenotyping the structural integrity by registering the
degree of free diffusion in a tissue as a general measure. The
“diffusivity” is described as the average of the sum of eigenvalues
whereas “fractional anisotropy” is described as an index which
reflects the degree of anisotropy within a voxel (the variation by
which the tissue diffusion contrasts to an idealised sphere).
Early ex-vivo cardiac DTI work was demonstrated that
cardiac DTI was feasible without destruction of the myocardial
architecture and also confirmed that the first and second
eigenvectors correlated with histological orientation of the
myofibres and sheetlet direction, respectively (98–100). Early
pilot studies also explored changes in fibre architecture in
pathologies such as myocardial infarction (101, 102). There are
several limitations associated with ex-vivo cardiac DTI regarding
the method/ duration of fixation of the tissue, the cardiac phase
in which the heart was fixed (i.e., in a systolic or diastolic
state), and the absence of normal loading conditions. Ex-vivo
work suggested a dynamic rearrangement of the myocytes during
contraction, but in recent years, the development of in-vivo dual-
phase cardiac DTI has built on this. Recent work has shown that
macroscopic LV hypertrophy is associated with sheetlet angle
during contraction (103, 104).
The application of DTI to a moving tissue, in particular the
cardiovascular system, is more challenging than in a static organ.
The relaxation time of the myocardium is shorter than in the
cerebral tissue, which imposes significant limitations on the echo
time that can be used. Moreover, inhomogeneity of the B0-field
is increased in the thoracic cavity, particularly at higher field
strengths in comparison with the brain. This results in a higher
incidence of artefacts, which can affect the diffusion-weighted
images. Furthermore, DTI in a beating heart with respiratory
motion and displacement of the myocardium during contraction
is challenging in that the diffusion of water is several orders of
magnitude smaller than bulkmotion. The sequences that are used
for ex-vivo imaging are highly motion-sensitive and therefore are
not necessarily suitable for in-vivo imaging. A number of other
novel DTI sequences have been proposed. The most broadly used
technique is the dual-gated stimulated echo acquisition mode
(STEAM) sequence. In brief, these involve three excitation pulses
applied over two successive heartbeats. This STEAM sequence is
relatively insensitive to cardiac motion however it is not robust
in arrhythmia. Cardiac DTI is also affected by cardiac strain.
The strain produced by myocardial deformation has an impact
on diffusion measurements. Proposed approaches to circumvent
this issue include imaging at the so-called “sweet-spot” which is
a time point, individual for a subject, where the temporal mean
of strain approaches zero, thereby eliminating the effect of strain,
typically at the mid-systolic or mid-diastolic phase of the cardiac
cycle (105, 106). Post-processing methods also allow to correct
for the effects of strain (107).
In vivo cardiac DTI has reported reproducibility and normal
ranges of helix and sheetlet angles in healthy hearts (94, 108–
111), and has since been used to explore a variety of pathologies
including myocardial infarction, cardiac amyloidosis, and both
dilated and hypertrophic cardiomyopathy (112–117). These
more recent studies have underlined the potential for DTI to
investigate architecture-related changes in disease in relation
to biomechanics and over time. Data from in-vivo dual-phase
cardiac DTI in patients with DCM combined with tagging data
and biomechanical modelling explored the relationship between
geometry and helix and sheetlet angle, concluding that helix
and sheetlet angle changes are likely to be maladaptive rather
than compensatory (117). A fascinating and elaborate study by
Nielles-Vallespin et al. (113) shed more detailed light on changes
in architecture in DCM and HCM; the authors were able to
conclude that the myocardium in hypertrophic cardiomyopathy
is permanently in a more systolic, contracted state whereas in
dilated cardiomyopathy the myocardium is in a more diastolic
state. This may potentially account for the predominant diastolic
impairment seen in hypertrophic cardiomyopathy compared
with the more prevalent systolic impairment seen in dilated
cardiomyopathy. Recent studies have also investigated the
changes in infarcted tissue comparing DTI with late gadolinium
enhancement imaging demonstrating changes in infarcted tissue,
suggesting there may be an opportunity to use DTI to evaluate
myocardial scar in place of using a gadolinium-based contrast
agent (118), and suggested that cardiac DTI may even provide
complementary information on remodelling post-myocardial
infarction (119). Technical developments in cardiac DTI are
ongoing with recent studies exploring the use of cardiac DTI at
7-Tesla (120).
There is no doubt that there is a crucial interplay between
the cardiac microstructure, and the biomechanical and electrical
functions of cardiac function and that cardiac DTI holds promise
in developing a deeper understanding of this relationship.
Recent years have seen significant developments in the cardiac
DTI, allowing a greater understanding of cardiac structure
and function in both health and disease. Though cardiac DTI
remains a research tool with ongoing work in optimisation of
the technique, in due course this advanced technology may
play a part in identifying novel biomarkers or response to
new therapies.
FOUR-DIMENSIONAL FLOW
Intracardiac blood flow and its velocities have played a very
important role in cardiovascular assessment. However, novel
imaging methods like four-dimensional flow CMR (4D flow
CMR) imaging are resulting in a paradigm shift as they inform
us about flow in all three-directions (Figure 6) (121). We already
know that the blood flow is complex, dynamic, and has a
diverse 3D profile (122). The fourth dimension in 4D flow
CMR imaging is time. More recently, 4D flow CMR has seen
significant development allowing for whole-heart cross-sectional
flow imaging in under 10 min (123–125).
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FIGURE 6 | Four-dimensional flow CMR acquisition.
Visualisation
One method to visualise 4D flow is to co-register the velocity
coded 2-dimensional flow over the cine planes. This provides
an instant and quick assessment of flow vectors depending on
the cine visualised (Figure 7). For example, a four-chamber
or two-chamber cine can then be used to visualise mitral
regurgitation jets using 4D flow CMR. Furthermore, 4D flow
CMR enables the visualisation of flow accelerations through
stenotic valvular or vascular lesions and can provide additional
information in challenging cases such as congenital heart disease
where haemodynamic effects of anatomical abnormalities are
not always clear. 4D flow CMR visualisation can be integrated
into routine CMR reporting and can add diagnostic advantage.
Valvular stenotic flow accelerations and pathological eccentricity
of the flow can be determined by visualisation of 2-directional
velocity vectors. This becomes clinically relevant, for example, an
eccentric aortic ejection flow direction would raise the suspicion
of bicuspid aortic valve or aortic stenosis (126, 127). Routine
visualisation of 2-directional vectors on four-chamber cine can
enhance detection of septal defects, flow acceleration in outflow
tracts, and valvular regurgitation (Figure 8).
Vortex Imaging
We are now developing a better understanding of blood flow
behaviour inside the ventricles using 4D flow CMR. Vortices
are formed in almost all chambers of the heart and major
vessels. Vortices can be due to optimum physiological flow (128),
pathological flow due to dilatation (129), or raised pressures
(130). Vortical flow in the main pulmonary artery is an example
of pathological flow and is associated with elevated main
pulmonary arterial pressure (131). Vortical blood flow in the
main pulmonary artery tends to be pathological and a threshold
>14.3% of the cardiac interval is associated with pulmonary
hypertension (sensitivity: 97%; specificity: 96%). Similarly, in
aortic root dilation, more helical flows with vortices have been
demonstrated as pathological (132). Another study also showed
that flow abnormalities may be a major contributor to aortic
dilation in patients with bicuspid aortic valve disease (133).
Quantification of 4D Flow
4D flow CMR not only helps to visualise but also allows to
quantify vascular, valvular, and intra-ventricular flow. These
include transvalvular flow, intra-cavity velocity or kinetic energy
(KE) assessment, vortex quantification, blood flow component
analysis, and haemodynamic forces quantification (134). From
the above-mentionedmethods, valvular flow quantification using
retrospective valve tracking is ready for clinical adoption as
it has been validated and has demonstrated superior accuracy
to standard 2D phase-contrast methods (134–136). The other
method which shows promising intra-/inter-observer reliability
is intra-cavity blood flow KE mapping (137). Most of the other
techniques remain research tools, which have offeredmechanistic
insight into several disease processes and are currently under
investigation of direct clinical applications.
Quantification of Transvalvular Flow
4D flow CMR in the context of retrospective valve tracking
allows quantification of flow through all four heart valves for the
same averaged cardiac cycle, whilst factoring in valve motion by
tracking the valve (138) (Figure 9). This valve tracking method
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FIGURE 7 | Overview of flow visualisation in the left atrium in a patient with mitral regurgitation secondary to P2 prolapse (orange arrow). 4D flow data is co-registered
with cines to demonstrate 2-directional vectors, which have speed encoded colour coding (0–40 cm/s). There is eccentric mitral regurgitation that is directed towards
the intra-atrial septum and swirls back into the left atrium (white arrows in panels 4–8). The mitral regurgitation jet almost fills the entire left atrium.
FIGURE 8 | Cine co-registered 4D flow visualisation can offer instant understanding of intra-cardiac shunts and other similar cardiac pathologies. In this figure, there is
atrial septal defect that was not clearly recognised on cine (A), however, with 2-directional vector visualisation in (B), there was an obvious left to right shunt. This was
quantified by retrospective valve tracking method and significant Qp, Qs was noted (C).
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FIGURE 9 | Left ventricular blood flow kinetic energy mapping in healthy, ageing, and in patients with myocardial infarction.
overcomes the limitations of conventional 2D phase-contrast
velocity encoded imaging or Doppler ultrasound-based through-
plane motion. Therefore, 4D flow CMR flow quantification
methods can be considered to be the non-invasive “gold-
standard” for intracardiac flow quantification (139–141). In
patients with limited apical ultrasound views, 4D flow CMR
may provide an alternative to assess peak E and A velocities for
LV diastolic function assessment. Moreover, 4D flow CMR can
be used to directly quantify regurgitant volumes by generating
a reformatted plane in the 4D volume data set that is exactly
perpendicular to the regurgitant jet (142). Software solutions with
automated valve tracking procedures reduce post-processing
time significantly and are becoming more readily available (143).
Quantification of Blood Flow Kinetic
Energy
4D flow CMR also allows us to quantify the KE of blood flow
through a chamber of the heart for the complete cardiac cycle.
The KE of a moving blood flow with mass (m) and velocity (v)
is KE = ½m × v2. In this equation mass is (blood viscosity)
× (voxel size). Using the KE formula, the whole left ventricular
blood flow KE can be quantified by summing the KE of each
individual voxel within the ventricular cavity. This is achieved by
superimposing the time-resolved endocardial contours defined
from cine images onto the 4D flow data to extract velocity
information. The analysis of KE is predominantly automated. As
this technique uses endocardial contours which have established
high reproducibility, a key strength of KE quantification is
its excellent intra-/inter-observer agreement and almost instant
haemodynamic assessment without needing any additional post-
processing (137). As LV blood flow KE takes into consideration
complete intra-cavity flow, it is a better marker of diastolic
function when compared to standard diastolic parameters
(Figure 9) (137). Furthermore, studies have shown how it is an
independent predictor of adverse remodelling post-myocardial
infarction (144) and even LV thrombus formation (145). This
emergent tool holds great potential for phenotyping cardiac
haemodynamics, informing diagnosis, and potentially predicting
disease course. Future trials are needed to evaluate its value in
informing treatment outcomes in cardiovascular diseases.
FUTURE PERSPECTIVES
The role of CMR and its inclusion in multiple guidelines across
the breadth of cardiology has been expanding steadily in recent
years. Whilst conventional techniques provide without doubt
the gold standard assessment for anatomy, function, and tissue
characterisation in a non-invasive radiation-free method, the
emergence of novel methods of CMR will allow incremental
value not only in the diagnosis, but also in the management
of more patients with cardiac pathology. It is only a matter
of time before the described techniques become more broadly
available to the cardiovascular imaging community and further
prognostic studies validate the utility of these techniques for
clinical translation.
CONCLUSION
CMR has a role of paramount importance in the assessment
and diagnosis of cardiovascular disease. We reviewed the
conventional CMR methods currently used in clinical practice
but also described novel methods likely to enter the clinical
arena in the future. With these novel methods, CMR can
successfully guide clinical management further by revealing
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clinically important clues related to cardiac anatomy and
function. Technical developments, advanced methods of
image acquisition, and a better understanding of cardiac
haemodynamics provide the foundation for further research and
validation of the newly emerging tools and techniques that are
being proved to be of extreme clinical importance.
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